CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 135 enrolled / 135 target
Drug / intervention
BMS-986012 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04702880
NCT04702880Phase 2CompletedMonitor (2.1/mo)Completion was 13mo ago
CompareCT.gov

A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Bristol-Myers Squibb·interventional·Posted Jan 11, 2021·Updated Jun 17, 2026

In Brief

A Phase 2 clinical trial evaluating BMS-986012, Carboplatin, and 2 other interventions for Extensive-stage Small Cell Lung Cancer. Completed, enrolled 135 participants across 39 sites in 11 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small Cell Lung Cancer
CountriesAustralia, Belgium, Canada, Greece, Italy, Japan, Netherlands, Poland, Romania, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 11, 2021
Enrollment StartMar 17, 2021
Primary CompletionMay 22, 2025
Study CompletionNov 28, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 5.5 years ago

Arms & Interventions

Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012experimental

Biological: BMS-986012Drug: CarboplatinDrug: EtoposideBiological: Nivolumab
Arm B: Carboplatin + Etoposide + Nivolumabexperimental

Drug: CarboplatinDrug: EtoposideBiological: Nivolumab

Interventions

BMS-986012biological

Specified dose on specified days

Carboplatindrug

Specified dose on specified days

Etoposidedrug

Specified dose on specified days

Nivolumabbiological

Specified dose on specified days